Compare BioNano Genomics Inc (BNGO) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs McDonald's Corp — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while McDonald's Corp trades at $269.28 (market cap $191.08B). The key difference: McDonald's Corp is far larger — about 14475.8× BioNano Genomics Inc's market cap, and McDonald's Corp pays a 2.77% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MCD | |
|---|---|---|
Market Cap | $13.20M | $191.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $341.06 |
52-Week Low | $1.09 | $264.54 |
Enterprise Value | $15.81M | $244.79B |
Volume | — | 2,230,036 |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
McDonald's (MCD) trades at $268.94, down 2.06% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly EPS results, with a miss in Q3 2025 but beats in Q4 2025 and Q1 2026. Revenue grew to $26.89 billion in 2025, with a net income margin of 31.62%. Recent news highlights the launch of the McDonald's NEXT strategy focusing on automation and better food to win back customers.
The outlook remains supported by strong analyst consensus with a $325.50 price target and 59.68% buy ratings, but risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. The stock offers a dividend yield with a recent $1.86 payout, appealing for income-focused investors amid current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
